glennkuajy

    • glennkuajyglennkuajy
      ·2021-06-28
      cool

      NIO: The Path To A $1 Trillion Valuation

      NIO is known by many as a large cap Chinese electric vehicle company.However, it is actually much more than that and possesses several key competitive advantages.We discuss how these factors could combine with its focus on China to transform it into a $1 trillion mega cap.NIO also has a strong foothold on autonomous mobility technology thanks to filing nearly 50 patents in the area and boasts AI-powered smart "cockpits.". Given that the mobility industry is becoming increasingly software-driven,
      NIO: The Path To A $1 Trillion Valuation
      2.84KComment
      Report
    • glennkuajyglennkuajy
      ·2021-06-25
      nice

      Panasonic sells its stake in Tesla for nearly $4 billion: report

      Japanese company says battery deal with Tesla will not be affected. Panasonic Corp. sold its entire
      Panasonic sells its stake in Tesla for nearly $4 billion: report
      2.50KComment
      Report
    • glennkuajyglennkuajy
      ·2021-06-25
      cool
      Sorry, this post has been deleted
      2.65KComment
      Report
    • glennkuajyglennkuajy
      ·2021-06-23
      wow
      Sorry, this post has been deleted
      2.79KComment
      Report
    • glennkuajyglennkuajy
      ·2021-06-22
      wow
      Sorry, this post has been deleted
      2.78KComment
      Report
    • glennkuajyglennkuajy
      ·2021-06-21
      cool
      Sorry, this post has been deleted
      2.91KComment
      Report
    • glennkuajyglennkuajy
      ·2021-06-18
      wow
      Sorry, this post has been deleted
      2.80KComment
      Report
    • glennkuajyglennkuajy
      ·2021-06-18
      wow

      Tesla Partner CureVac Says Will Find 'Sweet Spot' For COVID-19 Vaccine Despite Disappointing Data

      CureVac N.V.’s Chief Financial Officer Pierre Kemula is optimistic its COVID-19 vaccine could still be offered to certain age groups or as a booster, the Financial Timesreportedon Thursday.What Happened:Kemula told FT the German vaccine developer is still hopeful the jab could be offered to certain age groups or as a booster after data from CureVac’s late-stage trial of its international first-generation vaccine candidateshowed that it had only47% efficacy.“There is a lot of need for vaccines ou
      Tesla Partner CureVac Says Will Find 'Sweet Spot' For COVID-19 Vaccine Despite Disappointing Data
      3.02KComment
      Report
    • glennkuajyglennkuajy
      ·2021-06-15
      wow
      Sorry, this post has been deleted
      2.95KComment
      Report
    • glennkuajyglennkuajy
      ·2021-06-15
      ohh
      Sorry, this post has been deleted
      3.28KComment
      Report
       
       
       
       

      Most Discussed